Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
BMC Cancer|July 29, 2021
Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patientsGiuliana Cavalloni, Caterina Peraldo-Neia, Annamaria Massa, et al.
Cancers|April 30, 2021
A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma PatientCaterina Peraldo-Neia, Annamaria Massa, Francesca Vita, et al.
BMC Cancer|December 7, 2014
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical modelsCaterina Peraldo-Neia, Giuliana Cavalloni, Marco Soster, et al.
Frontiers in Medicine|August 24, 2023
Eosinophilic dermatosis of hematologic malignancy in patients with chronic lymphocytic leukemia/non-Hodgkin's B lymphoma: a single center prospective clinico-pathological studyAndrea Michelerio, Carlo Tomasini, Giacomo Fiandrino, et al.
Cancers|January 11, 2025
Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic CholangiocarcinomaAnnamaria Massa, Francesca Vita, Caterina Peraldo-Neia, et al.
BMC Cancer|November 20, 2010
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomasYmera Pignochino, Ivana Sarotto, Caterina Peraldo-Neia, et al.
Frontiers in Oncology|March 7, 2022
Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic CholangiocarcinomaAnnamaria Massa, Caterina Peraldo-Neia, Francesca Vita, et al.
Blood Cancer Journal|October 15, 2020
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosisAlessandra Carobbio, Paola Guglielmelli, Elisa Rumi, et al.
Oncotarget|April 20, 2017
Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasmsChiara Cavalloni, Elisa Rumi, Virginia V Ferretti, et al.
Breast Cancer Research and Treatment|December 15, 2010
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenibGiorgio Valabrega, Sonia Capellero, Giuliana Cavalloni, et al.
Pageof 6